Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 429-438

  Böhm, Daniel ^a   Keller, Ksenia ^a   Pieter, Julia ^a   Boehm, Nils ^a   Wolters, Dominik ^a   Siggelkow, Wulf ^a   Lebrecht, Antje ^a   Schmidt, Marcus ^a   Kölbl, Heinz ^a   Pfeiffer, Norbert ^a   Grus, Franz Hermann ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Biomarker; Breast cancer; Diagnosis; Proteomics; Tear fluids

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 3A; CALGRANULIN A; CIQ1 PROTEIN; IMMUNOGLOBULIN; TEAR PROTEIN; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; INTERMETHOD COMPARISON; LACRIMAL FLUID; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EYE PROTEINS; FEMALE; HUMANS; MIDDLE AGED; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84863457211     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1849     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Brekelmans CT, Seynaeve C, Bartels CC, et al: Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19: 924-930, 2001. (Pubitemid 32176266)
3. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312, 2007. (Pubitemid 350232263)
4. Tyers M and Mann M: From genomics to proteomics. Nature 422: 193-197, 2003. (Pubitemid 36362756)
5. Elrick MM, Walgren JL, Mitchell MD and Thompson DC: Proteomics: recent applications and new technologies. Basic Clin Pharmacol Toxicol 98: 432-441, 2006.
6. Banks RE, Dunn MJ, Hochstrasser DF, et al: Proteomics: new perspectives, new biomedical opportunities. Lancet 356: 1749-1756, 2000.
7. Li J, Zhang Z, Rosenzweig J, Wang YY and Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304, 2002. (Pubitemid 34809839)
8. Mathelin C, Cromer A, Wendling C, Tomasetto C and Rio MC: Serum biomarkers for detection of breast cancers: A prospective study. Breast Cancer Res Treat 96: 83-90, 2006.
9. Baskin Y and Yigitbasi T: Clinical proteomics of breast cancer. Curr Genomics 11: 528-536, 2010.
10. Huijbers A, Velstra B, Dekker TJ, et al: Proteomic serum biomarkers and their potential application in cancer screening programs. Int J Mol Sci 11: 4175-4193, 2010.
11. Paweletz CP, Trock B, Pennanen M, et al: Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 17: 301-307, 2001. (Pubitemid 34014685)
12. Li J, Zhao J, Yu X, et al: Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 11: 8312-8320, 2005. (Pubitemid 41746942)
13. Pawlik TM, Fritsche H, Coombes KR, et al: Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 89: 149-157, 2005. (Pubitemid 40253557)
14. de Noo ME, Deelder A, van der Werff M, Ozalp A, Mertens B and Tollenaar R: MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie 29: 501-506, 2006. (Pubitemid 44631671)
15. Villanueva J, Shaffer DR, Philip J, et al: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284, 2006. (Pubitemid 43121812)
16. Engwegen JY, Gast MC, Schellens JH and Beijnen JH: Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 27: 251-259, 2006.
17. Lebrecht A, Boehm D, Schmidt M, Koelbl H and Grus FH: Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry to detect breast cancer markers in tears and serum. Cancer Genomics Proteomics 6: 75-83, 2009.
18. Hudson ME, Pozdnyakova I, Haines K, Mor G and Snyder M: Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA 104: 17494-17499, 2007. (Pubitemid 350219866)
19. Hodgkinson VC, ElFadl D, Drew PJ, Lind MJ and Cawkwell L: Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. J Proteomics 74: 698-703, 2011.
20. Shi W, Meng Z, Chen Z, Luo J and Liu L: Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Mol Cell Biochem 347: 117-125, 2011.
21. Yang L, Guo S, Li Y, Zhou S and Tao S: Protein microarrays for systems biology. Acta Biochim Biophys Sin (Shanghai) 43: 161-171, 2011.
22. Bohm D, Keller K, Boehm N, et al: Antibody microarray analysis of the serum proteome in primary breast cancer patients. Cancer Biol Ther 12: 772-779 2011.
23. Bertucci F, Birnbaum D and Goncalves A: Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 5: 1772-1786, 2006. (Pubitemid 44688187)
24. Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96: 353-356, 2004.
25. Downes MR, Byrne JC, Dunn MJ, Fitzpatrick JM, Watson RW and Pennington SR: Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review. Biomarkers 11: 406-416, 2006. (Pubitemid 44364080)
26. Radpour R, Barekati Z, Kohler C, Holzgreve W and Zhong XY: New trends in molecular biomarker discovery for breast cancer. Genet Test Mol Biomarkers 13: 565-571, 2009.
27. Lebrecht A, Boehm D, Schmidt M, Koelbl H, Schwirz RL and Grus FH: Diagnosis of breast cancer by tear proteomic pattern. Cancer Genomics Proteomics 6: 177-182, 2009.
28. de Freitas Campos C, Cole N, Van Dyk D, et al: Proteomic analysis of dog tears for potential cancer markers. Res Vet Sci 85: 349-352, 2008.
29. Shevchenko A, Loboda A, Ens W, Schraven B, Standing KG and Shevchenko A: Archived polyacrylamide gels as a resource for proteome characterization by mass spectrometry. Electrophoresis 22: 1194-1203, 2001. (Pubitemid 32409392)
30. Perkins DN, Pappin DJ, Creasy DM and Cottrell JS: Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20: 3551-3567, 1999. (Pubitemid 30007252)
31. UniProt Consortium: Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res 39: D214-D219, 2011.
32. Szklarczyk D, Franceschini A, Kuhn M, et al: The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39: D561-D568, 2011.
33. Cline MS, Smoot M, Cerami E, et al: Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2: 2366-2382, 2007.
34. Grus FH, Podust VN, Bruns K, et al: SELDI-TOF-MS ProteinChip array profiling of tears from patients with dry eye. Invest Ophthalmol Vis Sci 46: 863-876, 2005. (Pubitemid 41321022)
35. Nacken W, Roth J, Sorg C and Kerkhoff C: S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 60: 569-580, 2003.
36. Tamesa MS, Kuramitsu Y, Fujimoto M, et al: Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis 30: 2168-2181, 2009.
37. El Yazidi-Belkoura I, Adriaenssens E, Vercoutter-Edouart AS, Lemoine J, Nurcombe V and Hondermarck H: Proteomics of breast cancer: outcomes and prospects. Technol Cancer Res Treat 1: 287-296, 2002.
38. Gast MC, Schellens JH and Beijnen JH: Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116: 17-29, 2009.
39. Shin BK, Wang H and Hanash S: Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J Mammary Gland Biol Neoplasia 7: 407-413, 2002. (Pubitemid 38438258)
40. Zhou P, Lowery M, J AD and Kuiken T: Towards improved myoelectric prosthesis control: high density surface EMG recording after targeted muscle reinnervation. Conf Proc IEEE Eng Med Biol Soc 4: 4064-4067, 2005. (Pubitemid 46229829)
41. Böhm D, Keller K, Wehrwein N, et al: Serum proteome profiling of primary breast cancer indicates a specific biomarker profile. Oncol Rep 26: 1051-1056, 2011.
42. Oner F, Savas I and Numanoglu N: Immunoglobulins and complement components in patients with lung cancer. Tuberk Toraks 52: 19-23, 2004.
43. Liu W, Liu B, Xin L, et al: Down-regulated expression of complement factor I: a potential suppressive protein for gastric cancer identified by serum proteome analysis. Clin Chim Acta 377: 119-126, 2007. (Pubitemid 44908239)
44. Gast MC, van Gils CH, Wessels LF, et al: Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clin Chem Lab Med 47: 694-705, 2009.
45. Markiewski MM, DeAngelis RA, Benencia F, et al: Modulation of the antitumor immune response by complement. Nat Immunol 9: 1225-1235, 2008.
46. Markiewski MM and Lambris JD: Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 30: 286-292, 2009.